Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 2/20 | 0.35 |
| ▸ | GLI1 | P08151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733722 | 0.82 | PRCP (0.44) | PRCPNOS2NOS3NOS1DPP4 | |
| SCHEMBL4733728 | 0.82 | PRCP (0.44) | PRCPNOS2NOS3NOS1DPP4 | |
| SCHEMBL4733724 | 0.82 | PRCP (0.44) | PRCPNOS2NOS3NOS1DPP4 | |
| SCHEMBL9579255 | 0.81 | — | — | |
| SCHEMBL4685341 | 0.80 | PRCP (0.46) | PRCPNOS2NOS3NOS1DPP4 | |
| SCHEMBL29471063 | 0.80 | PRCP (0.42) | PRCPNOS2NOS3NOS1DPP4 | |
| SCHEMBL4012939 | 0.80 | PRCP (0.46) | PRCPNOS2NOS3NOS1DPP4 | |
| SCHEMBL1969951 | 0.80 | NOS2 (0.50) | PRCPNOS2NOS3NOS1DPP4 | |
| SCHEMBL1969952 | 0.80 | NOS2 (0.50) | PRCPNOS2NOS3NOS1DPP4 | |
| SCHEMBL2496024 | 0.77 | PRCP (0.41) | PRCPNOS2NOS3NOS1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
| EP-1613338-A4 | TAMANDARIN ANALOGS AND FRAGMENTS THEREOF AND METHODS OF MAKING AND USING | JOULLIE MADELEINE M (US) | 2009-06-24 | — | — | EP | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| EP-1613338-A2 | TAMANDARIN ANALOGS AND FRAGMENTS THEREOF AND METHODS OF MAKING AND USING | Joullie, Madeleine M. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004084812-A2 | TAMANDARIN ANALOGS AND FRAGMENTS THEREOF AND METHODS OF MAKING AND USING | JOULLIE MADELEINE M (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | FOXM1, F3, RB1 | PRCP 1593/4885NOS2 874/4885NOS3 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.